Literature DB >> 15802805

Effects of oxypeucedanin on hKv1.5 and action potential duration.

Jae Soon Eun1, Jung Ah Park, Bok Hee Choi, Sun Kyung Cho, Dae Keun Kim, Yong Geun Kwak.   

Abstract

A furocoumarin derivative, oxypeucedanin, was purified from Angelica dahurica, and its effects on the human Kv1.5 (hKv1.5) channel and on the cardiac action potential duration (APD), were examined using the patch-clamp technique and the conventional microelectrode technique. Oxypeucedanin inhibited the hKv1.5 current in a concentration-dependent manner, with an IC(50) value of 76 nM, while it had no effect on human eag-related gene (HERG) current. Oxypeucedanin induced an initial fast decline of hKv1.5 current during depolarizations. The inhibition of hKv1.5 channel by oxypeucedanin was voltage-dependent, especially at depolarizing pulses between -40 and 0 mV which corresponds to the voltage range of the channel's opening. Oxypeucedanin also slowed the deactivation time course, resulting in a tail crossover phenomenon. Additionally, oxypeucedanin prolonged the APD of rat atrial and ventricular muscles in a dose-dependent manner. These results suggest that oxypeucedanin is a kind of open-channel blocker of the hKv1.5 channel and it prolongs the APD; therefore, it is an excellent candidate as an antiarrhythmic drug for atrial fibrillation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15802805     DOI: 10.1248/bpb.28.657

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  2 in total

Review 1.  Natural products modulating the hERG channel: heartaches and hope.

Authors:  Jadel M Kratz; Ulrike Grienke; Olaf Scheel; Stefan A Mann; Judith M Rollinger
Journal:  Nat Prod Rep       Date:  2017-08-02       Impact factor: 13.423

2.  A Network Pharmacology-Based Study on Irritable Bowel Syndrome Prevention and Treatment Utilizing Shenling Baizhu Powder.

Authors:  Meng Meng; Chen Bai; Bo Wan; Luqing Zhao; Zhe Li; Danyan Li; Shengsheng Zhang
Journal:  Biomed Res Int       Date:  2021-11-23       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.